METHOD FOR DIAGNOSING CHRONIC PULMONARY ASPERGILLOSIS Russian patent published in 2024 - IPC A61B6/03 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to mycology and infectious diseases, and can be used for diagnosing chronic pulmonary aspergillosis (CPA). Mycological examination involves microscopy and culture of bronchoalveolar lavage (BAL), CT of lungs with assessment of changes of pulmonary tissue. Presence of rheumatologic diseases is additionally determined, fibrobronchoscopy is performed with obtaining bronchial secretion and subsequent determination of the presence of antigen to Aspergillus in BAL. Calculation of probability of presence of CPA is performed by means of formulas: LDF1 = -3.7+5.57·X1+2.6·X2+0.04·X3+0.42·X4+1.14·X5; LDF2 = -1.91+0.05·X1+1.14·X2+1.85·X3+2.51·X4-0.54·X5, where X1 is the presence of mycological confirmation of the diagnosis, wherein if the diagnosis is not confirmed, then X1=0, if the diagnosis is confirmed, then X1=1; X2 is the presence of the “air sickle” symptom on the CT-scans, in the absence of the “air sickle” symptom on the CT-scans X2=0, in the presence of the “air sickle” symptom on the CT-scans X2=1; X3 is presence of “frosted glass” symptom on CT-scans, in absence of “frosted glass” symptom on CT-scans X3=0, in presence of “frosted glass” symptom on CT-scans X3=1; X4 is presence of rheumatological diseases, in the absence of rheumatological diseases X4=0, in the presence of rheumatological diseases X4=1; X5 is presence of Aspergillus spp. in BAL, in the absence of Aspergillus spp. in BAL X5=0, in the presence of Aspergillus spp. in BAL X5=1. If LDF1>LDF2, CPA is diagnosed.

EFFECT: method enables predicting the nature of the pulmonary involvement by evaluating the clinical-laboratory and radiation signs in the patients with previous pulmonary diseases without compromising the immune status.

1 cl, 5 dwg, 3 tbl, 3 ex